$CCEL
CRYO CELL INTERNATIONAL INC

2024 Q2 Form 10-Q Financial Statement

#000095017024044493 Filed on April 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $8.043M $7.852M
YoY Change 3.48% 0.36%
Cost Of Revenue $2.025M $2.160M
YoY Change -5.53% 4.5%
Gross Profit $6.018M $5.692M
YoY Change 6.9% -1.13%
Gross Profit Margin 74.83% 72.49%
Selling, General & Admin $4.021M $4.340M
YoY Change -0.44% 11.88%
% of Gross Profit 66.82% 76.24%
Research & Development $241.1K $502.9K
YoY Change -20.87% 537.91%
% of Gross Profit 4.01% 8.84%
Depreciation & Amortization $112.2K $86.05K
YoY Change -68.39% -76.74%
% of Gross Profit 1.86% 1.51%
Operating Expenses $4.262M $4.871M
YoY Change -7.37% 23.06%
Operating Profit $1.392M $821.2K
YoY Change 35.37% -51.21%
Interest Expense $329.3K -$26.78K
YoY Change -148.17% -105.74%
% of Operating Profit 23.66% -3.26%
Other Income/Expense, Net $80.66K $60.00
YoY Change 3796.71% -100.01%
Pretax Income $1.472M $794.5K
YoY Change 324.97% -34.58%
Income Tax $816.4K $238.3K
% Of Pretax Income 55.45% 29.99%
Net Earnings $655.8K $556.2K
YoY Change 196.76% -27.46%
Net Earnings / Revenue 8.15% 7.08%
Basic Earnings Per Share $0.08 $0.07
Diluted Earnings Per Share $0.08 $0.07
COMMON SHARES
Basic Shares Outstanding 8.104M 8.287M
Diluted Shares Outstanding 8.232M 8.325M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.530M $979.6K
YoY Change -9.61% -55.74%
Cash & Equivalents $469.2K $247.1K
Short-Term Investments $1.060M $732.5K
Other Short-Term Assets $435.5K $990.4K
YoY Change -58.9% 135.21%
Inventory $708.2K $755.2K
Prepaid Expenses $651.8K $535.3K
Receivables $6.831M $6.727M
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.16M $9.452M
YoY Change -1.52% -11.14%
LONG-TERM ASSETS
Property, Plant & Equipment $22.16M $22.56M
YoY Change 21.19% 56.4%
Goodwill $1.941M $1.941M
YoY Change 0.0% 0.0%
Intangibles $955.2K $972.2K
YoY Change -32.5% -32.45%
Long-Term Investments $0.00 $308.0K
YoY Change -100.0% 0.0%
Other Assets $30.25M $26.47M
YoY Change -17.11% -35.54%
Total Long-Term Assets $52.41M $52.26M
YoY Change -10.32% -5.83%
TOTAL ASSETS
Total Short-Term Assets $10.16M $9.452M
Total Long-Term Assets $52.41M $52.26M
Total Assets $62.57M $61.71M
YoY Change -9.0% -6.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.828M $2.997M
YoY Change -54.94% 26.78%
Accrued Expenses $3.217M $4.171M
YoY Change 31.78% 35.64%
Deferred Revenue $9.581M $9.395M
YoY Change 1.32% 1.53%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $171.6K $168.6K
YoY Change 8.3% 6.41%
Total Short-Term Liabilities $19.45M $19.37M
YoY Change -1.32% 2.42%
LONG-TERM LIABILITIES
Long-Term Debt $8.356M $8.392M
YoY Change -1.76% -1.83%
Other Long-Term Liabilities $53.86M $44.29M
YoY Change 30.09% -7.56%
Total Long-Term Liabilities $53.86M $52.68M
YoY Change 7.92% 9.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.45M $19.37M
Total Long-Term Liabilities $53.86M $52.68M
Total Liabilities $73.31M $72.05M
YoY Change 5.3% 7.82%
SHAREHOLDERS EQUITY
Retained Earnings -$29.95M -$30.60M
YoY Change 45.02% 46.63%
Common Stock $44.05M $43.87M
YoY Change 1.92% 1.88%
Preferred Stock
YoY Change
Treasury Stock (at cost) $24.84M $23.60M
YoY Change 6.04% 3.17%
Treasury Stock Shares
Shareholders Equity -$10.74M -$10.34M
YoY Change
Total Liabilities & Shareholders Equity $62.57M $61.71M
YoY Change -9.0% -6.69%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $655.8K $556.2K
YoY Change 196.76% -27.46%
Depreciation, Depletion And Amortization $112.2K $86.05K
YoY Change -68.39% -76.74%
Cash From Operating Activities $1.773M -$356.9K
YoY Change -10.84% -121.71%
INVESTING ACTIVITIES
Capital Expenditures $1.752M $457.7K
YoY Change 20.21% 21.86%
Acquisitions
YoY Change
Other Investing Activities -$1.003M $116.7K
YoY Change 753.11% -114.12%
Cash From Investing Activities -$2.755M -$341.1K
YoY Change 74.9% -71.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.203M 539.0K
YoY Change -281.42% -169.74%
NET CHANGE
Cash From Operating Activities 1.773M -356.9K
Cash From Investing Activities -2.755M -341.1K
Cash From Financing Activities 1.203M 539.0K
Net Change In Cash 222.1K -159.0K
YoY Change -189.16% -51.96%
FREE CASH FLOW
Cash From Operating Activities $1.773M -$356.9K
Capital Expenditures $1.752M $457.7K
Free Cash Flow $21.56K -$814.6K
YoY Change -95.94% -164.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-02-29
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40767
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
CY2024Q1 dei City Area Code
CityAreaCode
813
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
749-2100
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
CCEL
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8104477
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
247112
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
406067
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
732481
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
574183
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3939638
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3822300
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6726893
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
535295
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
615407
CY2024Q1 us-gaap Inventory Net
InventoryNet
755160
CY2023Q4 us-gaap Inventory Net
InventoryNet
768877
CY2024Q1 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
76825
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
122113
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
378310
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
389950
CY2024Q1 us-gaap Assets Current
AssetsCurrent
9452076
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9452837
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21605273
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20996883
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
972154
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
989121
CY2024Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
5223980
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
5260119
CY2024Q1 us-gaap Goodwill
Goodwill
1941411
CY2023Q4 us-gaap Goodwill
Goodwill
1941411
CY2024Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20492749
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20492749
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
958022
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1033157
CY2024Q1 ccel Deposits And Other Assets
DepositsAndOtherAssets
757109
CY2023Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
746493
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30653425
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30771050
CY2024Q1 us-gaap Assets
Assets
61710774
CY2023Q4 us-gaap Assets
Assets
61220770
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2996658
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3174584
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3916898
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5170809
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
168623
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
165641
CY2024Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1972728
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1222728
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
253981
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
225686
CY2024Q1 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
666667
CY2023Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1200000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9394821
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9704553
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19370376
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20864001
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
42603661
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41186800
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
39050
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
44226
CY2024Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
8391738
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8430037
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
768961
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
851938
CY2024Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
52678410
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51388001
CY2024Q1 us-gaap Liabilities
Liabilities
72048786
CY2023Q4 us-gaap Liabilities
Liabilities
72252002
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14849246
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8254977
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14849246
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8286785
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
148492
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
148492
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43718498
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43411143
CY2024Q1 us-gaap Treasury Stock Value
TreasuryStockValue
23602061
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
23431685
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30602941
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31159182
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-10338012
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11031232
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61710774
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61220770
CY2024Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7852235
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7824415
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2160468
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2067364
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4339645
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3878903
CY2024Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-5176
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-164701
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
502889
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78834
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
33186
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
280844
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
7031012
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
6141244
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
821223
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1683171
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
274971
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-3681
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-45288
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
63
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1268
CY2024Q1 us-gaap Interest Expense
InterestExpense
256459
CY2023Q1 us-gaap Interest Expense
InterestExpense
466231
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26713
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-468644
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
794510
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1214527
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
238269
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
447715
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
556241
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
766812
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8277844
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8467074
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8325027
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8474737
CY2024Q1 us-gaap Profit Loss
ProfitLoss
556241
CY2023Q1 us-gaap Profit Loss
ProfitLoss
766812
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
86047
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
369950
CY2024Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-5176
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-164701
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
274971
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-3681
CY2024Q1 ccel Realized And Unrealized Gain On Interest Rate Swap Contract
RealizedAndUnrealizedGainOnInterestRateSwapContract
-45288
CY2023Q1 ccel Realized And Unrealized Gain On Interest Rate Swap Contract
RealizedAndUnrealizedGainOnInterestRateSwapContract
0
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
307355
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
313174
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
288760
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
186904
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
5348
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
5444
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
75135
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
79324
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
439413
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
665419
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-80112
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
13587
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-49856
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-230459
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-11640
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-5796
CY2024Q1 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
10616
CY2023Q1 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
18339
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-931007
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
221749
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1253911
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-510907
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-54682
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-80048
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1107129
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
913634
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-356865
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1643926
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
457722
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
375600
CY2024Q1 ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
743811
CY2023Q1 ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1017738
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
860484
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
191400
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-341049
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1201938
CY2024Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
170376
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
243201
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
40665
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
29646
CY2024Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
200000
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
500000
CY2024Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
950000
CY2023Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
538959
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-772847
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-158955
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
42603661
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41186800
CY2024Q1 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2023Q1 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
695695
CY2024Q1 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
30179
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-330859
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
406067
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1703958
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
247112
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1373099
CY2024Q1 ccel Construction Costs Payable
ConstructionCostsPayable
219748
CY2023Q1 ccel Construction Costs Payable
ConstructionCostsPayable
536707
CY2024Q1 ccel Duke License Agreement Payable
DukeLicenseAgreementPayable
533333
CY2023Q1 ccel Duke License Agreement Payable
DukeLicenseAgreementPayable
0
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
443829
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
441336
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
57630
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
33072
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11031232
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
307355
CY2024Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
170376
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
556241
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-10338012
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
313174
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
243201
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
766812
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-687517
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
51998482
CY2024Q1 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9394821
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2024Q1 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
11052
CY2023Q1 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
10432
CY2024Q1 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
30179
CY2023Q1 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
26436
CY2024Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
716621
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
695695
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6726893
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9394821
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9704553
CY2024Q1 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
9253
CY2024Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
716621
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6576240
CY2024Q1 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
10250022
CY2024Q1 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
10099369
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6726893
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
50891353
CY2024Q1 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
5297596
CY2024Q1 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
4190467
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
51998482
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
CY2023Q1 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
26436
CY2023Q1 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
8098
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
633966
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
CY2023Q1 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
10373235
CY2023Q1 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
9894720
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6522456
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
45586386
CY2023Q1 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
6404429
CY2023Q1 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
5490795
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
46500020
CY2023Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-4000
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-45288
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2024Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2024Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2023Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
307000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
313000
CY2024Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
275000
CY2024Q1 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product Warranty and Cryo-Cell Cares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Program</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at February 29, 2024 and November 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7852235
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7824415
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2160468
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2067364
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
821223
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1683171
CY2024Q1 us-gaap Interest Expense
InterestExpense
256459
CY2023Q1 us-gaap Interest Expense
InterestExpense
466231
CY2024Q1 us-gaap Assets
Assets
61710774
CY2023Q4 us-gaap Assets
Assets
61220770
CY2024Q1 ccel Inventory Collection Kits
InventoryCollectionKits
54739
CY2023Q4 ccel Inventory Collection Kits
InventoryCollectionKits
47739
CY2024Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2024Q1 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
5979140
CY2023Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
6028996
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
972154
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
989121
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2024Q1 us-gaap Ratio Of Indebtedness To Net Capital1
RatioOfIndebtednessToNetCapital1
3.5
CY2024Q1 ccel Minimum Debt Service Coverage Ratio
MinimumDebtServiceCoverageRatio
1.25
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
8560361
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8595678
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
168623
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
165641
CY2024Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
8391738
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8430037
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
8560361
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8595678
CY2024Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
0
CY2023Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
207919
CY2024Q1 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
198607
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
556241
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
766812
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8277844
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8467074
CY2024Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
47183
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7663
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8325027
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8474737
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
507278
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y4M6D
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.14
CY2024Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
367868
CY2024Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
7.48
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
114193
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
225686
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
768961
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
851938
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1022942
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1077624
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.1
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
103000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.13
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
77783
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.2
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
139410
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.07
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
CY2024Q1 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6594269
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6562461
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
958022
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1033157
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
253981
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
230071
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
435970
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
458026
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
38247
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
139372
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1022942
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M29D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y29D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
89354
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
88395
CY2023Q4 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
13108064

Files In Submission

Name View Source Status
0000950170-24-044493-index-headers.html Edgar Link pending
0000950170-24-044493-index.html Edgar Link pending
0000950170-24-044493.txt Edgar Link pending
0000950170-24-044493-xbrl.zip Edgar Link pending
ccel-20240229.htm Edgar Link pending
ccel-20240229.xsd Edgar Link pending
ccel-ex10_5.htm Edgar Link pending
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ccel-20240229_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending